Xilio Therapeutics Inc
NASDAQ:XLO
Intrinsic Value
Xilio Therapeutics, Inc. operates as a biotechnology company. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of XLO.
Fundamental Analysis
Balance Sheet Decomposition
Xilio Therapeutics Inc
| Current Assets | 48.1m |
| Cash & Short-Term Investments | 44.7m |
| Other Current Assets | 3.4m |
| Non-Current Assets | 12.8m |
| PP&E | 11.1m |
| Other Non-Current Assets | 1.7m |
| Current Liabilities | 16m |
| Accounts Payable | 1.1m |
| Accrued Liabilities | 11.5m |
| Other Current Liabilities | 3.4m |
| Non-Current Liabilities | 8.1m |
| Other Non-Current Liabilities | 8.1m |
Earnings Waterfall
Xilio Therapeutics Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-79.1m
USD
|
|
Operating Income
|
-79.1m
USD
|
|
Other Expenses
|
2.7m
USD
|
|
Net Income
|
-76.4m
USD
|
Free Cash Flow Analysis
Xilio Therapeutics Inc
XLO Profitability Score
Profitability Due Diligence
Xilio Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Xilio Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
XLO Solvency Score
Solvency Due Diligence
Xilio Therapeutics Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Score
Xilio Therapeutics Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
XLO Price Targets Summary
Xilio Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for XLO is 5.61 USD with a low forecast of 5.05 USD and a high forecast of 6.3 USD.
Ownership
XLO Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
XLO Price
Xilio Therapeutics Inc
| Average Annual Return | -41.47% |
| Standard Deviation of Annual Returns | 59.08% |
| Max Drawdown | -98% |
| Market Capitalization | 29.3m USD |
| Shares Outstanding | 27 540 000 |
| Percentage of Shares Shorted | 0.19% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Xilio Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Waltham, Massachusetts and currently employs 74 full-time employees. The company went IPO on 2021-10-22. The firm has built its geographically precise solutions (GPS) platform to rapidly engineer molecules, including cytokines and other biologics. The Company’s most advanced product candidates are in clinical development. Its XTX101 is a clinical-stage, tumor-selective anti-CTLA-4 mAb, which is designed to improve upon the therapeutic index of existing anti-CTLA-4 therapies by localizing its activity in the TME. The company initiated a Phase I/II trial to evaluate XTX101 in patients with advanced solid tumors, and enrollment is ongoing. XTX202 is an engineered form of IL-2, which is masked with a protein domain to prevent binding activity until the protein domain is cleaved off by TME-associated proteases. The company initiated a Phase I/II trial to evaluate XTX202 in patients with solid tumors.
You don't have any saved screeners yet
